MedPage Today) — BARCELONA — A drug targeting immunoglobulin G (IgG) currently approved for myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP) now looks like it could take the rheumatology field by storm, if phase…
Rheumatology Indication Looks Promising for Efgartigimod

Leave a Comment Leave a Comment